Observational study of trastuzumab biosimilar in patients with HER2-positive breast cancer under routine clinical practice conditions in Morocco
Abstract Background Trastuzumab, a recombinant humanized monoclonal antibody has demonstrated clinical benefits in women with human epidermal growth factor receptor type 2 (HER2)-positive breast cancer in early and metastatic disease settings. However, real-world data on trastuzumab biosimilars are...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
BMC
2026-04-01
|
| Rangatū: | BMC Cancer |
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.1186/s12885-026-16005-2 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|